Need To Accelerate Drug Development? What Are You Missing?

All drug developers – from academics to large pharma – are tight on resources, so understandably are focusing on maximal drug activity. This can speed up candidate nomination or win seed funding, but a pure focus on drug action can leave gaping holes in the key facts needed for human trials.

To enable fast Phase I trials, we need to know the rest of the picture, especially minimum active levels, unintended binding, duration of action, and species-specific biology. Skipping these steps can hinder development, harm patients, or kill drug – and then it’s back to the starting gate.

This article walks through some scenarios and describes a team filling a unique role in the industry: Charles River’s Scientific Advisory Services.